Active ingredientBerotralstatCat. No. P-B056-001CAS 1809010-50-1Family · Pharmaceutical analytical standards
Berotralstat
An inhibitor of plasma kallikrein, the enzyme that releases bradykinin, which causes the swellings of hereditary angioedema. Approved in the United States at the end of 2020, it was the first oral therapy, one capsule a day, to prevent attacks of this rare disease. This family brings together the active ingredient, labelled standards, nitrosamines and other impurities.
Did you know?The enzyme it blocks owes its name to the pancreas: in 1934 Eugen Werle found it in abundance in this organ and called it kallikrein, from the Greek kallikreas, meaning "pancreas".
Go to the active ingredient →Active ingredientBerotralstatCat. No. P-B056-001CAS 1809010-50-1
Isotopically labelledBerotralstat-d4Cat. No. P-B056-002
Isotopically labelledRac-Berotralstat-d4Cat. No. P-B056-003
NitrosamineN-Nitroso BerotralstatCat. No. P-B056-004
NitrosamineN-Nitroso Berotralstat Impurity 1Cat. No. P-B056-005
Impurity(S)-BerotralstatCat. No. P-B056-006CAS 1809010-51-2
ImpurityBerotralstat Impurity 1Cat. No. P-B056-007CAS 209917-93-1
ImpurityBerotralstat Impurity 2Cat. No. P-B056-008CAS 1809015-77-7
ImpurityBerotralstat Impurity 3Cat. No. P-B056-009CAS 640287-99-6
ImpurityBerotralstat Impurity 4Cat. No. P-B056-010CAS 1809015-78-8
ImpurityBerotralstat Impurity 5Cat. No. P-B056-011CAS 1809015-79-9
Impurityrac-BerotralstatCat. No. P-B056-012CAS 1809010-16-9No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.